The active component, Fenspiride, is commonly used for symptomatic support in conditions involving inflammatory or irritative states of the respiratory and ear, nose, and throat (ENT) tracts. The active component is used in situations involving certain distressing symptoms across therapeutic domains related to airway function. The substance is historically associated with symptomatic relief in bronchopulmonary conditions.

This medication may be part of symptomatic management across a range of conditions presenting with acute or chronic symptoms, including acute bronchitis, laryngitis, rhinopharyngitis, sinusitis, bronchial asthma, and stable Chronic Obstructive Pulmonary Disease (COPD). It is commonly used to help with symptoms related to allergic rhinitis.

---

Quick Fact: Symptom Domain Focus

Symptom Domain Focus	Benefit Focus	Clinical Context
Irritative Cough	Helps address symptoms related to heightened physiological activity.	Commonly used across conditions presenting with acute episodes.
Sputum/Mucus	Assists in easing the overall symptom load.	Conditions involving episodic or fluctuating manifestations.
Airway Narrowing	Assists with maintaining functional stability.	Conditions where symptoms may intensify temporarily.

---

Relief for Acute Inflammatory Airway Conditions

This medication is applied in addressing the core discomfort arising from local irritation and swelling in the airways, contributing to improved comfort during symptomatic episodes such as acute bronchitis, laryngitis, and sinusitis.

Eligibility Map: Who Can and Cannot Use Elofenal (Fenspiride) — Official Regulatory Information

This section describes the mandatory eligibility and non-eligibility rules for Elofenal (Fenspiride Hydrochloride) based strictly on authoritative government regulatory documentation.

Eligibility Scope

Classification	Official Regulatory Status
Populations for whom use is allowed (as stated in label):	Adults and Adolescents were formerly permitted, a status now restricted by overriding cardiac contraindications.
Populations for whom use is not recommended (if applicable):	Breastfeeding women are a population where use is officially documented as not recommended.
Populations for whom use is contraindicated:	Patients with a known hypersensitivity; patients with history of QT interval prolongation or Torsades de pointes; patients using concurrent QT-prolonging medicinal products.
Age-related eligibility rules:	Use is contraindicated in children younger than 2 years of age; the cardiac contraindication applies to all other age groups.
Condition-specific eligibility rules:	Caution is required for use in patients with renal impairment; Caution is required for use in patients with hepatic impairment.
Pregnancy and lactation eligibility status:	Contraindicated in pregnant women; not recommended in breastfeeding women.

---

Eligibility Classifications (High-Level)

Classification	Description
Eligibility severity classification:	The highest level of restriction is Absolute Contraindication.
Regulatory basis:	Primarily based on a European Medicines Agency (EMA) referral action due to confirmed proarrhythmic cardiac risk.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is formally contraindicated in any patient with a history of cardiac repolarization abnormalities.
• Children under 2 years of age are listed as an ineligible population in official labeling.
• Pregnant women are formally contraindicated from using the medicine, and use is not recommended during lactation.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Elofenal by imposing absolute contraindications on populations with cardiac vulnerabilities and certain comorbidities. This strict exclusion is due to the confirmed risk of severe heart rhythm abnormalities, which applies to all authorized patient age groups.

The official regulatory documentation identifies the interactions for Elofenal (Fenspiride) as primarily pharmacodynamic in nature, which results in strict constraints on co-administration with other substances.

The most critical restriction is the formal contraindication against combining Elofenal with medicinal products known to prolong the QTc interval. This restriction is mandatory due to a documented additive effect on ventricular repolarisation, which significantly increases the risk of serious ventricular arrhythmias such as Torsades de Pointes, as determined by European regulatory reviews.

In addition to this severe cardiac risk, other contraindicated combinations include co-administration with Monoamine Oxidase Inhibitors (MAOIs), a restriction explicitly stated in certain official labeling texts.

Pharmacodynamic effects extend to the central nervous system. Co-administration of Elofenal with other CNS depressants—including sedative drugs, opioid analgesics, and certain other antihistamines—may lead to an additive central depressant effect. This same potentiation is documented for the consumption of alcohol (ethanol), which enhances the sedative outcomes of the medicine. Regulatory sources do not provide specific documentation regarding pharmacokinetic interactions involving CYP enzymes or drug transporters, nor do they include mandatory timing separation requirements for administration.

Enzyme Inhibition and Prostaglandin Reduction

Elofenal acts by inhibiting the cyclooxygenase (COX) enzymes, which are critical components of the arachidonic acid cascade. Specifically, it is a non-selective, competitive inhibitor of both COX-1 and COX-2 isoforms. This targeted inhibition suppresses the conversion of arachidonic acid into prostaglandins—chemical mediators that regulate local physiological responses, including vascular tone and nociceptor thresholds.

---

Signal Modulation

By lowering the local concentration of prostaglandins, the drug modulates the peripheral pain-signaling system. This pathway effect decreases the activation threshold of nociceptors (pain receptors), altering the signal transmission originating from damaged or inflamed tissues. Furthermore, Elofenal influences signaling within central pain processing pathways, altering the overall output signal.

How to Use Elofenal (Diclofenac) — Administration Guidelines

This section outlines the administration of Diclofenac (marketed as Elofenal), focusing on standard procedural usage instructions. The correct use depends on the specific dosage form prescribed.

Dosing and Administration

Administration Route	Typical Dosing Regimen	Administration Specifics
Oral (Tablets/Capsules)	Typically 100 mg to 200 mg total daily dose, divided throughout the day, or 100 mg once daily for extended-release forms.	Immediate-release forms or powder should be taken on an empty stomach. Tablets/capsules must be swallowed whole without crushing, splitting, or chewing.
Oral (Powder)	Generally a single 50 mg dose, used as needed.	Mix the powder packet contents only with 1 to 2 ounces of plain water and drink immediately.
Topical (Gel)	Applied four times daily (e.g., 2g or 4g per application, depending on the joint).	Measure the dose using the provided dosing card. Avoid covering the treated area with heat or occlusive dressings.
Intravenous (IV)	37.5 mg, repeated as needed every 6 hours, up to 150 mg maximum daily dose.	Administer as an IV bolus injection over no less than 15 seconds.

Procedural Use Rules

• Lowest Effective Dose: Use the lowest effective dose for the shortest duration consistent with individual treatment goals.
• Missed Dose: If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose; in that case, skip the missed dose and do not double the next dose.
• Elderly Patients: Dosing for older patients should typically start at the low end of the dosing range.

Research Evidence / Overview of Studies for Elofenal

The existing research on Elofenal (Fenspiride) describes studies conducted across different types of respiratory and ear, nose, and throat (ENT) conditions. The available studies were designed to explore symptoms and functional measures in specific patient groups. This overview describes the research structure and the kind of findings that were described in the studies, while also highlighting what remains uncertain in the evidence landscape.

---

Evidence for Use in Acute Respiratory and ENT Conditions

Research exploring short-term symptom changes associated with Elofenal involved Randomized Controlled Trials (RCTs) and various other clinical observations. These studies explored the medication's effect during episodes where symptoms become more noticeable. Research examined patient populations including adults and children experiencing acute irritative or inflammatory infections of the airways, such as acute bronchitis or rhinopharyngitis. Studies examined patient-reported outcomes describing perceived discomfort, focusing on the intensity of coughing and the frequency of expectoration.

In these short-term studies, findings describe patterns observed in the studies related to measured changes in overall symptom intensity when using composite clinical scores. Some trials reported that the studies monitored the time elapsed until patients achieved a defined threshold of symptom change. However, findings were mixed across some studies regarding the statistical significance of measured changes for specific, individual symptoms, such as the severity of cough alone.

---

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Evidence for chronic conditions comes from RCTs and comparative clinical studies that were conducted in adults with stable COPD and chronic bronchitis, primarily assessing the medication as a supplement to existing maintenance therapy. Researchers examined outcomes reflecting daily functioning by measuring pulmonary function indices (such as FEV1) and exploring physical capability through tests like the 6-minute walk test. Studies report how symptoms evolved in the observed populations, describing patterns in measured scores related to patient-reported quality of life and symptom frequency over defined time intervals.

---

Research Gaps and Areas of Uncertainty

The research base identifies key limitations. Sample sizes were modest in many trials, meaning the results apply only to the populations studied. Follow-up durations were limited, especially for acute indications, and data for long-term outcomes are limited for chronic outcomes. Research frequently relied on subjective patient-reported outcomes, which can introduce variability. Data for specific complex subgroups, such as pregnant women or patients with advanced disease, remain insufficient.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: R03DX03 (Fenspiride)

Common questions about Elofenal (FAQ)

Q: How quickly should I expect Elofenal to start working for pain?

A: Official product information indicates that the active ingredient, diclofenac, is generally absorbed rapidly after oral administration. However, the onset of effect can vary among individuals. This is influenced by the specific type of product formulation, as well as whether the medicine is taken with or without food.

Q: What are the most commonly reported side effects of taking Elofenal?

A: According to clinical trial data summarized in regulatory documents, the most common adverse reactions reported by more than 2% of patients relate to the gastrointestinal and nervous systems. These may include abdominal pain, nausea, diarrhea, dyspepsia (indigestion), flatulence, and headache.

Q: Are there any long-term side effects associated with regular Elofenal use?

A: As a member of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, long-term use of the drug is associated with a risk of potential renal (kidney) injury. Regulatory sources state that monitoring of liver function and blood counts is advised for treatments extending over a longer duration.

Q: Does alcohol affect how Elofenal works in the body?

A: Co-administration of alcohol with diclofenac has been linked to an increased risk of serious gastrointestinal adverse events. Specifically, the combination may raise the risk of issues like internal bleeding and ulcer formation.

Q: What other medicines should not be taken while using Elofenal?

A: Examples of drugs usually not recommended for co-administration include other NSAIDs, anticoagulants (blood thinners), and aspirin. Additionally, certain medications that may increase the risk of kidney problems, such as ACE inhibitors, are often listed in warning statements.

Q: What scientific studies support the use of Elofenal for arthritis?

A: Diclofenac is formally indicated and supported by clinical data for managing the signs and symptoms of inflammatory joint conditions. This includes both osteoarthritis and rheumatoid arthritis, according to the official product label.

Q: Is Elofenal safe for people with a history of stomach ulcers?

A: Regulatory information indicates that diclofenac carries an increased risk of serious gastrointestinal problems, including severe bleeding and ulceration. For populations with a prior history of these issues, regulatory information states the medicine should be used with extreme caution.

Q: Why do doctors recommend stopping Elofenal before surgery?

A: The official label contains a restriction that contraindicates the use of diclofenac during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. This restriction is due to the documented increase in the risk of serious cardiovascular events in this specific setting.

Q: Does Elofenal affect blood thinning or coagulation?

A: Diclofenac is known to interfere with how platelets function, which are critical for blood clotting. The co-administration of diclofenac with an anticoagulant (blood thinner) significantly increases the overall risk of serious gastrointestinal bleeding.

Q: Is Elofenal known to cause any skin reactions or rashes?

A: Yes, official safety information reports that diclofenac can cause serious skin adverse events, such as Stevens-Johnson Syndrome (SJS). Safety warnings emphasize that the medication must be discontinued immediately if a rash or other sign of a serious reaction appears.

Q: What is the maximum amount of time someone should generally take Elofenal?

A: Regulatory guidance emphasizes that to minimize the risk of serious side effects, the use of the drug is recommended at the lowest effective dose for the shortest duration possible. This principle applies to all NSAIDs.

Q: Can people with kidney problems take Elofenal?

A: The drug must be used with caution in populations with impaired renal (kidney) function, as it may worsen the condition. In cases of advanced kidney disease, use is generally avoided unless the benefit-risk profile is deemed acceptable.

Q: Why does Elofenal have a warning about heart risks?

A: Diclofenac, like other NSAIDs, carries a Boxed Warning—the most serious type of warning—because it increases the risk of serious cardiovascular thrombotic events. These events include heart attack and stroke, which can potentially be fatal.

Q: Can people with asthma safely use Elofenal?

A: Diclofenac is formally contraindicated in people who have experienced asthma attacks, hives (urticaria), or other allergic-type reactions after taking aspirin or any other NSAID medicine.

Q: How does Elofenal affect the liver?

A: Official product information notes that diclofenac can cause elevations in liver tests. Serious adverse events, including liver failure, have been reported. Regulatory safety statements mandate that the medicine be discontinued if abnormal liver tests persist or become worse.

Q: Can using Elofenal cause fluid retention or swelling?

A: Yes, regulatory documents note that fluid retention and edema (swelling) have been observed in some patients using diclofenac. In populations with conditions such as heart failure or pre-existing fluid retention, the medicine is advised to be used with caution.

Q: What kind of research has been done on Elofenal for chronic pain?

A: The indications for diclofenac are supported by research and clinical data showing effectiveness in managing chronic inflammatory conditions. These include osteoarthritis and rheumatoid arthritis, which are recognized sources of chronic pain.

Q: Is there a risk of dependency or addiction with Elofenal?

A: According to the regulatory label, the active ingredient in Elofenal, diclofenac, is not classified as a controlled substance. Official documents do not report a risk of addiction or physical dependence for this medication.

Q: Can Elofenal cause changes in mood or sleep?

A: The list of adverse reactions reported occasionally in clinical settings includes central nervous system effects. These effects may involve central nervous system issues such as nervousness, anxiety, insomnia (difficulty sleeping), and depression.

Q: Why do some people say Elofenal causes headaches?

A: Headache is frequently reported in clinical studies of diclofenac. Regulatory documentation lists it as one of the most common adverse reactions, having been reported by more than 2% of patients in trials.

Q: Should I worry about an allergic reaction to Elofenal?

A: Yes, serious and sometimes fatal allergic-type reactions (anaphylactic reactions) have been reported with diclofenac. The medicine is contraindicated if there is a known hypersensitivity to the drug or a history of allergic reactions to other NSAIDs.

Q: Why is Elofenal prescribed for both pain and inflammation?

A: Diclofenac is an NSAID that works by inhibiting cyclooxygenase (COX) enzymes. Since these enzymes are responsible for producing prostaglandins—which are key chemical mediators of both pain and inflammation—blocking them helps relieve both symptoms concurrently.

Q: Does Elofenal interact with common over-the-counter pain relievers?

A: Official safety documents advise against combining diclofenac with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including some available over-the-counter. This combination is typically avoided as it significantly increases the risk of serious side effects in the digestive system.

How to Store and Dispose of Elofenal

Elofenal (Fenspiride Hydrochloride) must be stored and handled according to the instructions provided in its official regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at temperatures not exceeding 25 C (77 F).
Handling	Do not refrigerate or freeze the medicine.
Protection	Keep the container tightly sealed and protected from direct sunlight.

For the oral syrup formulation, the product must be used within 6 months after the initial opening. The medicine must, at all times, be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Elofenal must be disposed of in accordance with local and national regulations. To protect the environment, the medicine and its container must not be allowed to enter sewers, surface water, or ground water.